Citius Pharmaceuticals (CTXR) Competitors

Citius Pharmaceuticals (NASDAQ:CTXR) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation, dividends and community ranking.

Does the MarketBeat Community favor CTXR or VTGN?

Vistagen Therapeutics received 74 more outperform votes than Citius Pharmaceuticals when rated by MarketBeat users. Likewise, 72.31% of users gave Vistagen Therapeutics an outperform vote while only 62.28% of users gave Citius Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Citius Pharmaceuticals	Outperform Votes 208 62.28%	Underperform Votes 126 37.72%
Vistagen Therapeutics	Outperform Votes 282 72.31%	Underperform Votes 108 27.69%

Which has more volatility & risk, CTXR or VTGN?

Citius Pharmaceuticals has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.

Do analysts rate CTXR or VTGN?

Citius Pharmaceuticals presently has a consensus price target of $4.00, suggesting a potential upside of 925.64%. Vistagen Therapeutics has a consensus price target of $13.50, suggesting a potential upside of 357.63%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Citius Pharmaceuticals is more favorable than Vistagen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Vistagen Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Does the media favor CTXR or VTGN?

In the previous week, Citius Pharmaceuticals and Citius Pharmaceuticals both had 2 articles in the media. Vistagen Therapeutics' average media sentiment score of 1.87 beat Citius Pharmaceuticals' score of 0.46 indicating that Vistagen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vistagen Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has higher earnings & valuation, CTXR or VTGN?

Vistagen Therapeutics has higher revenue and earnings than Citius Pharmaceuticals. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Vistagen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$32.54M	-$0.24	-1.60
Vistagen Therapeutics	$971K	82.66	-$29.36M	-$2.07	-1.43

Do insiders and institutionals hold more shares of CTXR or VTGN?

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are owned by institutional investors. 15.0% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 1.0% of Vistagen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Is CTXR or VTGN more profitable?

Citius Pharmaceuticals has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -3,421.85%. Vistagen Therapeutics' return on equity of -35.12% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-44.65%	-39.39%
Vistagen Therapeutics	-3,421.85%	-35.12%	-32.35%

Summary

Vistagen Therapeutics beats Citius Pharmaceuticals on 10 of the 16 factors compared between the two stocks.